BCL2L1 and neoplasm: The CSCs were identified from breast (MDA231 and MCF7), prostate (PC3 and LnCap), and ovary (A2780 P, A2780 ADR, and A2780 CIS) tumor cell lines based on their ability to form spheroids in serum free conditions, elevated expression of CSC surface markers, high expression of ABC drug transporters (ABCG2), cell survival protein (Cyclin D1), oncogenes (c-Myc), and the ability to escape cell death/apoptosis (Bcl-xl).